炎症性肠病相关IgA肾病:全国研究与系统综述
该回顾性多中心研究纳入24例活检证实的炎症性肠病相关IgA肾病患者,与134例原发性IgA肾病对照,分析临床表现、治疗及肾脏结局。结果显示炎症性肠病相关IgA肾病起病时炎症病变常见,长期结局不一,与原发性IgA肾病演变相似。
要点
- 炎症性肠病相关IgA肾病起病时高血压占41.7%,尿蛋白肌酐比>100 mg/mmol者占70.8%。
- 牛津分类M1占57%、E1占48%、S1占76%、T1-2占57%、C1-2占38%。
- 平均随访7.2年,16.7%患者出现不良肾脏结局,与原发性IgA肾病相似。
核心结论
- 炎症性肠病相关IgA肾病起病时炎症病变常见,长期结局可变,与原发性IgA肾病演变相似。
研究设计与样本
- 回顾性多中心研究,纳入24例炎症性肠病相关IgA肾病患者,与134例无炎症性肠病的原发性IgA肾病患者对照,并进行集中组织学复审。
主要发现
- 克罗恩病和溃疡性结肠炎分别占炎症性肠病相关IgA肾病病例的75%和25%。
- 23例(平均9年前)先诊断炎症性肠病,23.6%患者IgA肾病起病时炎症性肠病处于活动期。
- 高血压占41.7%,尿蛋白肌酐比>100 mg/mmol占70.8%(平均254 mg/mmol)。
- eGFR>60 mL/min/1.73 m2者13/24例,仅1例需要透析。
- 牛津分类M1占57%、E1占48%、S1占76%、T1-2占57%、C1-2占38%;50%病例使用激素。
临床怎么用
- 对炎症性肠病患者应关注肾脏受累,起病时评估高血压、蛋白尿及肾功能。
- 炎症性肠病相关IgA肾病治疗可参考原发性IgA肾病,但需结合炎症性肠病活动性个体化决策。
局限性
- 回顾性设计,样本量小(24例),随访时间有限,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about clinical characteristics and kidney outcomes in patients with biopsy-proven immunoglobulin A nephropathy (IgAN) in a context of inflammatory bowel disease (IBD). METHODS: We conducted a retrospective multicentre study with a centralized histological review to analyse the presentation, therapeutic management and outcome of 24 patients suffering from IBD-associated IgAN relative to a cohort of 134 patients with primary IgAN without IBD. RESULTS: Crohn's disease and ulcerative colitis accounted for 75 and 25% of IBD-associated IgAN cases, respectively. IBD was diagnosed before IgAN in 23 cases (a mean of 9 years previously) and was considered active at IgAN onset in 23.6% of patients. Hypertension was present in 41.7% of patients. The urinary protein:creatinine ratio exceeded 100 mg/mmol in 70.8% of patients (mean 254 mg/mmol). Estimated glomerular filtration rate (eGFR) was >60 mL/min/1.73 m2 in 13/24 patients and only 1 patient required dialysis. In the Oxford mesangial hypercellularity, endocapillary cellularity, segmental sclerosis and interstitial fibrosis/tubular atrophy with crescents classification of renal biopsies, 57% were M1, 48% E1, 76% S1, 57% T1-2 and 38% C1-2. Steroids were administered in 50% of cases. After a mean follow-up of 7.2 years, 4 patients (16.7%) had a poor kidney outcome: end-stage renal disease (n = 3) or a >50% decrease in eGFR from initial values (n = 1). A similar evolution was observed in patients with primitive IgAN. CONCLUSIONS: This first case series suggests that IBD-associated IgAN has frequent inflammatory lesions at onset and variable long-term outcomes.
引用
- Joher N, Gosset C, Guerrot D, et al. Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transplant. 2022. PMID: 33416845. doi:10.1093/ndt/gfaa378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。